Sionna Therapeutics, Inc. Common Stock Study result
Review the key takeaways and the transcript of this earnings call.
- Sionna Therapeutics announced top line data from two clinical programs: the precision CF phase two trial of Sionna 719 added to Trikafta, and the phase one trial of Sionna 451-based proprietary dual combinations.
- The precision CF phase two trial did not meet its key activity endpoint, showing a mean placebo-adjusted sweat chloride change of minus one millimoles per liter with a p value of 0.7, below the predefined clinically meaningful threshold of ten millimoles per liter.
- 719 was generally well tolerated with no serious adverse events and no clinically meaningful trends in adverse events, including liver function events.
- The phase one dual combination trial evaluating 451 with 2222 and 109 achieved its safety, tolerability, and pharmacokinetic (PK) objectives, exceeding target exposure levels set prior to the precision CF outcome.
- The preferred dual combination identified was 451 plus 2222, with favorable tolerability and exposure profiles; some dose-limiting events occurred with twice-daily dosing of 2222 but resolved without sequelae.
- At the end of Q2, Sionna had approximately $268 million in cash and is undertaking actions to preserve capital.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first five paragraphs, organized by speaker.
Good morning, and welcome to the Sionna Therapeutics conference call. At this time, all participants are in a listen-only mode. After today's presentation, there will be an opportunity to ask questions. You will need to press star one one on your telephone to queue. Please note that this event is being recorded. I will now turn the call over to Juliet Labadorf, senior director of investor relations. Juliet, you may now begin.
Thank you. Good morning, and welcome to today's conference call. Joining me are Mike Cloonan, our President and Chief Executive Officer, and Charlotte McKee, our Chief Medical Officer. Also joining us for the Q&A session is Elena Ridloff, our Chief Financial Officer. Following our prepared remarks, we will open the call to questions. Before we begin, I would like to remind you that today's discussion will include forward-looking statements about our future expectations, plans, and prospects. These statements are subject to risks and uncertainties that may cause actual results to differ materially from those projected. A description of these risks can be found in our most recent 10-Q filed with the SEC, as well as any subsequent SEC filings. Any forward-looking statements speak only as of today's date, and we assume no obligation to update any forward-looking statements made on today's call.
With that, I will turn the call over to Mike Cloonan, our CEO.
Thanks, Juliet, and good morning, everyone. Thank you for joining us. Today, we are announcing top-line data from two clinical programs, our PreciSION CF phase IIa proof-of-concept trial of SION-719 added to Trikafta, and our phase I trial of SION-451-based proprietary dual combinations. Before we discuss the results, I would like to thank the people who participated in these studies, their families, and all those involved in executing the trial. I also want to recognize the Sionna team for their incredible dedication, focus, and commitment. We are deeply disappointed to announce that the PreciSION CF phase IIa trial did not meet its key activity endpoint, as measured by change in sweat chloride. Given these data, we are not continuing development of seven one nine as an add-on to standard of care.
The phase I dual combination trial evaluating SION-451 in combination with SION-2222 and SION-109 achieved its safety, tolerability, and PK objectives, including exceeding target exposure that we had determined prior to the PreciSION CF outcome. We are actively analyzing the phase IIa data and our translational framework to help assess the potential profile and next steps for SION-451 plus SION-2222 dual combination. We will be data-driven and disciplined, including taking actions to preserve capital. Charlotte will now walk us through the results, and I will return to discuss our next steps. After that, we will open the call for Q&A.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
14 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring